Topical Spironolactone in the Treatment of Evaporative Dry Eye Disease
June 2023
in “
Cureus
”
New to Spironolactone? There is a guide in the encyclopedia. Read the guide → 
Studysummary In a retrospective study, researchers found that topical spironolactone improved tear film quality and reduced inflammation related to meibomian gland dysfunction and evaporative dry eye in patients, demonstrating good tolerability and suggesting it as a potential therapy for managing the condition.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
A retrospective observational study on 102 patients with dry eye disease found that topical spironolactone, a medication with anti-mineralocorticoid, anti-androgenic, and anti-inflammatory properties, improved self-reported global assessment scores and visual acuity. The treatment also led to significant improvements in keratitis, conjunctival staining scores, and lid margin inflammation, particularly in patients with higher Schirmer's tear test scores. The study concluded that spironolactone may improve tear film quality and address the inflammatory processes associated with Meibomian gland dysfunction and evaporative dry eye. However, further studies are needed to explore the long-term effects of this treatment.
